Avanos to be Acquired for $25 Per Share in Cash
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Apr 14 2026
0mins
Source: PRnewswire
- Acquisition Agreement: Avanos Medical has entered into a definitive agreement with American Industrial Partners, valuing the transaction at approximately $1.272 billion, with stockholders receiving $25 per share in cash, representing a 72.1% premium over the closing price on April 13, indicating strong market confidence in the company.
- Board Approval: The Avanos Board unanimously approved the transaction, believing it will maximize shareholder value and create new opportunities for employees, reflecting the company's strong momentum in the medical technology sector and its potential for future growth.
- Timeline for Completion: The acquisition is expected to close in the second half of 2026, subject to shareholder approval and customary conditions under antitrust laws, after which Avanos will become a private entity and its stock will no longer be listed on the NYSE.
- Strategic Partnership Outlook: AIP expressed admiration for Avanos' management team and product strength, with the partnership set to enhance Avanos' innovation trajectory and competitive positioning, signaling a promising future for the company’s long-term success.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy AVNS?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on AVNS
About AVNS
Avanos Medical, Inc. is a medical technology company focused on delivering medical device solutions. It offers healthcare needs, such as providing nutrition to patients from hospital to home and reducing the use of opioids while helping patients move from surgery to recovery. The Specialty Nutrition Systems portfolio of products includes enteral feeding, which consist of MIC-KEY enteral feeding tubes and Corpak patient feeding solutions, and Neonate solutions feeding products consist of NeoMed neonatal and pediatric feeding solutions. It also includes Nexus TKO, an anti-reflux needleless connector technology. The Pain Management and Recovery is a portfolio of non-opioid pain solutions including surgical pain and recovery products such as ON-Q and ambIT surgical pain pumps and Game Ready cold and compression therapy systems, as well as Radiofrequency Ablation solutions, which provide invasive pain relief therapies, such as COOLIEF, Trident and ESSENTEC RFA products.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Investigation Alerts for Multiple Company Mergers
- Helix Merger Investigation: Helix Energy Solutions is set to be acquired by Hornbeck Offshore Services, with Helix shareholders expected to own approximately 45% of the combined entity, raising concerns about whether the Helix Board breached fiduciary duties by failing to ensure a fair process in the transaction.
- TopBuild Acquisition Details: TopBuild will be acquired by QXO, allowing shareholders to choose between $505 in cash or 20.2 shares of QXO stock per TopBuild share, with the deal's total consideration being approximately 45% cash and 55% stock, prompting investigations into whether the transaction offers fair value, especially as it falls below the 52-week high of $559.47.
- Avanos Acquisition Situation: Avanos is being acquired by American Industrial Partners for $25.00 per share, amounting to an enterprise value of approximately $1.272 billion, with investigations focusing on whether the Avanos Board failed to conduct a fair process to ensure shareholder value in the deal.
- Affinity Bancshares Transaction: Affinity Bancshares will be acquired by Fidelity for $23.00 per share, representing a total transaction value of approximately $142.8 million, with investigations examining whether the Board breached fiduciary duties by not ensuring the fairness of the transaction for shareholders.
See More
Class Action Developments for Multiple Companies' Shareholders
- XOMA Shareholder Payout: XOMA Royalty Corporation is set to be sold to Ligand Pharmaceuticals for $39.00 per share in cash, which is expected to provide substantial returns for shareholders and enhance its market appeal.
- RE/MAX Shareholder Options: Shareholders of RE/MAX Holdings, Inc. will have the choice of receiving either 5.152 shares of the combined company or $13.80 in cash per share, which will strengthen its competitive position in the real estate market.
- Galera Merger Shares: Following the merger with Obsidian Therapeutics, Inc., Galera Therapeutics, Inc. shareholders will own approximately 1.8% of the combined company, indicating its potential for integration in the biotechnology sector.
- Avanos Cash Return: Avanos Medical, Inc. is being sold to affiliates of American Industrial Partners for $25.00 per share in cash, which is expected to provide direct cash returns to shareholders and enhance its financial stability.
See More
Avanos Medical Reports Strong Q1 2026 Earnings with Revenue Growth
- Significant Revenue Growth: Avanos Medical reported Q1 2026 revenue of $182.2 million, an 8.8% year-over-year increase that exceeded market expectations by $12.2 million, indicating strong performance in the medical device sector.
- Strong Specialty Nutrition Systems Performance: The Specialty Nutrition Systems (SNS) segment achieved net sales of $124.0 million, a $22.9 million increase from the prior year, reflecting the segment's continued competitive strength in the market.
- Stable Pain Management and Recovery Segment: The Pain Management and Recovery (PM&R) segment reported net sales of $56.3 million, remaining flat compared to the previous year, which provides a stable foundation for future growth despite the lack of growth in this area.
- 2026 Sales Outlook: Avanos expects sales in 2026 to range between $700 million and $720 million, primarily benefiting from tariff mitigation following its exit from the Chinese market, showcasing the company's positive outlook on future market conditions.
See More
Investor Rights Law Firm Investigates Multiple Companies
- Merger Investigation: Halper Sadeh LLC is investigating Helix Energy Solutions Group, Inc. (NYSE: HLX) for its merger with Hornbeck Offshore Services, Inc., where Helix shareholders will own approximately 45% of the combined company, potentially impacting shareholder rights and future earnings.
- Cash and Stock Options: TopBuild Corp. (NYSE: BLD) is set to be sold to QXO, Inc., allowing shareholders to choose between receiving $505.00 in cash or 20.2 shares of QXO common stock for each TopBuild share, which may influence shareholder returns and decision-making.
- Acquisition Price Confirmation: Avanos Medical, Inc. (NYSE: AVNS) is being sold to affiliates of American Industrial Partners for $25.00 per share in cash, and shareholders need to assess whether this price is fair and its implications for the company's future.
- Shareholder Rights Protection: Affinity Bancshares, Inc. (NASDAQ: AFBI) plans to sell to Fidelity BancShares (N.C.) for $23.00 per share in cash, with the price subject to adjustment based on adjusted stockholders' equity, prompting shareholders to actively understand their legal rights and options.
See More
Investor Rights Law Firm Investigates Multiple Companies
- Investigation Background: Halper Sadeh LLC is investigating companies including Whitestone REIT, Soleno Therapeutics, Odyssey Marine Exploration, and Avanos Medical for potential violations of federal securities laws and breaches of fiduciary duties, which may impact shareholder rights.
- Whitestone REIT Transaction: Whitestone REIT is being sold to Ares Management Corporation for $19.00 per share, and Halper Sadeh LLC may seek to increase the consideration to ensure shareholders receive fair compensation.
- Soleno Therapeutics Transaction: Soleno Therapeutics, Inc. is being sold for $53.00 per share in cash, and Halper Sadeh LLC encourages shareholders to understand their legal rights, potentially requesting additional disclosures to protect shareholder interests.
- Avanos Medical Transaction: Avanos Medical, Inc. is being sold to affiliates of American Industrial Partners for $25.00 per share, and Halper Sadeh LLC may advocate for higher consideration and other remedies for shareholders.
See More
Investor Rights Law Firm Investigates Multiple Companies
- Shareholder Rights Investigation: Halper Sadeh LLC is investigating the sale of Leggett & Platt, Incorporated, where shareholders will receive 0.1455 shares of Somnigroup common stock for each share of Leggett & Platt, resulting in approximately 9% ownership in the combined company, potentially impacting shareholder rights and future earnings.
- Cash Acquisition Details: Avanos Medical, Inc. is being sold to American Industrial Partners for $25.00 per share in cash, prompting shareholders to consider the implications of this transaction on their investments and rights.
- Select Medical Holdings Transaction: Select Medical Holdings Corporation is set to be sold for $16.50 per share in cash to a consortium led by its executives and directors, urging shareholders to understand the potential impacts of this deal and their legal options.
- Merger Transaction Analysis: The merger between Galera Therapeutics, Inc. and Obsidian Therapeutics, Inc. is expected to result in Galera shareholders owning approximately 1.8% of the combined company, necessitating attention to changes in shareholder rights and potential financial impacts post-merger.
See More
Investigation Alerts for Multiple Company Mergers
- Helix Merger Investigation: Helix Energy Solutions is set to be acquired by Hornbeck Offshore Services, with Helix shareholders expected to own approximately 45% of the combined entity, raising concerns about whether the Helix Board breached fiduciary duties by failing to ensure a fair process in the transaction.
- TopBuild Acquisition Details: TopBuild will be acquired by QXO, allowing shareholders to choose between $505 in cash or 20.2 shares of QXO stock per TopBuild share, with the deal's total consideration being approximately 45% cash and 55% stock, prompting investigations into whether the transaction offers fair value, especially as it falls below the 52-week high of $559.47.
- Avanos Acquisition Situation: Avanos is being acquired by American Industrial Partners for $25.00 per share, amounting to an enterprise value of approximately $1.272 billion, with investigations focusing on whether the Avanos Board failed to conduct a fair process to ensure shareholder value in the deal.
- Affinity Bancshares Transaction: Affinity Bancshares will be acquired by Fidelity for $23.00 per share, representing a total transaction value of approximately $142.8 million, with investigations examining whether the Board breached fiduciary duties by not ensuring the fairness of the transaction for shareholders.
See More
Class Action Developments for Multiple Companies' Shareholders
- XOMA Shareholder Payout: XOMA Royalty Corporation is set to be sold to Ligand Pharmaceuticals for $39.00 per share in cash, which is expected to provide substantial returns for shareholders and enhance its market appeal.
- RE/MAX Shareholder Options: Shareholders of RE/MAX Holdings, Inc. will have the choice of receiving either 5.152 shares of the combined company or $13.80 in cash per share, which will strengthen its competitive position in the real estate market.
- Galera Merger Shares: Following the merger with Obsidian Therapeutics, Inc., Galera Therapeutics, Inc. shareholders will own approximately 1.8% of the combined company, indicating its potential for integration in the biotechnology sector.
- Avanos Cash Return: Avanos Medical, Inc. is being sold to affiliates of American Industrial Partners for $25.00 per share in cash, which is expected to provide direct cash returns to shareholders and enhance its financial stability.
See More
Avanos Medical Reports Strong Q1 2026 Earnings with Revenue Growth
- Significant Revenue Growth: Avanos Medical reported Q1 2026 revenue of $182.2 million, an 8.8% year-over-year increase that exceeded market expectations by $12.2 million, indicating strong performance in the medical device sector.
- Strong Specialty Nutrition Systems Performance: The Specialty Nutrition Systems (SNS) segment achieved net sales of $124.0 million, a $22.9 million increase from the prior year, reflecting the segment's continued competitive strength in the market.
- Stable Pain Management and Recovery Segment: The Pain Management and Recovery (PM&R) segment reported net sales of $56.3 million, remaining flat compared to the previous year, which provides a stable foundation for future growth despite the lack of growth in this area.
- 2026 Sales Outlook: Avanos expects sales in 2026 to range between $700 million and $720 million, primarily benefiting from tariff mitigation following its exit from the Chinese market, showcasing the company's positive outlook on future market conditions.
See More
Investor Rights Law Firm Investigates Multiple Companies
- Merger Investigation: Halper Sadeh LLC is investigating Helix Energy Solutions Group, Inc. (NYSE: HLX) for its merger with Hornbeck Offshore Services, Inc., where Helix shareholders will own approximately 45% of the combined company, potentially impacting shareholder rights and future earnings.
- Cash and Stock Options: TopBuild Corp. (NYSE: BLD) is set to be sold to QXO, Inc., allowing shareholders to choose between receiving $505.00 in cash or 20.2 shares of QXO common stock for each TopBuild share, which may influence shareholder returns and decision-making.
- Acquisition Price Confirmation: Avanos Medical, Inc. (NYSE: AVNS) is being sold to affiliates of American Industrial Partners for $25.00 per share in cash, and shareholders need to assess whether this price is fair and its implications for the company's future.
- Shareholder Rights Protection: Affinity Bancshares, Inc. (NASDAQ: AFBI) plans to sell to Fidelity BancShares (N.C.) for $23.00 per share in cash, with the price subject to adjustment based on adjusted stockholders' equity, prompting shareholders to actively understand their legal rights and options.
See More
Investor Rights Law Firm Investigates Multiple Companies
- Investigation Background: Halper Sadeh LLC is investigating companies including Whitestone REIT, Soleno Therapeutics, Odyssey Marine Exploration, and Avanos Medical for potential violations of federal securities laws and breaches of fiduciary duties, which may impact shareholder rights.
- Whitestone REIT Transaction: Whitestone REIT is being sold to Ares Management Corporation for $19.00 per share, and Halper Sadeh LLC may seek to increase the consideration to ensure shareholders receive fair compensation.
- Soleno Therapeutics Transaction: Soleno Therapeutics, Inc. is being sold for $53.00 per share in cash, and Halper Sadeh LLC encourages shareholders to understand their legal rights, potentially requesting additional disclosures to protect shareholder interests.
- Avanos Medical Transaction: Avanos Medical, Inc. is being sold to affiliates of American Industrial Partners for $25.00 per share, and Halper Sadeh LLC may advocate for higher consideration and other remedies for shareholders.
See More
Investor Rights Law Firm Investigates Multiple Companies
- Shareholder Rights Investigation: Halper Sadeh LLC is investigating the sale of Leggett & Platt, Incorporated, where shareholders will receive 0.1455 shares of Somnigroup common stock for each share of Leggett & Platt, resulting in approximately 9% ownership in the combined company, potentially impacting shareholder rights and future earnings.
- Cash Acquisition Details: Avanos Medical, Inc. is being sold to American Industrial Partners for $25.00 per share in cash, prompting shareholders to consider the implications of this transaction on their investments and rights.
- Select Medical Holdings Transaction: Select Medical Holdings Corporation is set to be sold for $16.50 per share in cash to a consortium led by its executives and directors, urging shareholders to understand the potential impacts of this deal and their legal options.
- Merger Transaction Analysis: The merger between Galera Therapeutics, Inc. and Obsidian Therapeutics, Inc. is expected to result in Galera shareholders owning approximately 1.8% of the combined company, necessitating attention to changes in shareholder rights and potential financial impacts post-merger.
See More
